ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

ClinicalTrials.gov ID: NCT00883688

Public ClinicalTrials.gov record NCT00883688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Study identification

NCT ID
NCT00883688
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
24 participants

Conditions and interventions

Interventions

  • Bevacizumab Drug
  • Lapatinib Drug

Drug

Eligibility (public fields only)

Age range
Up to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2009
Primary completion
Mar 31, 2015
Completion
Mar 31, 2015
Last update posted
Aug 25, 2020

2009 – 2015

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Stanford University Medical Center Stanford California 94305
Children's Memorial Hospital Chicago Illinois 60614
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Children's Hospital of Pittsburgh Pittsburgh Pennsylvania 15213
St. Jude Children's Research Hospital Memphis Tennessee 38105
University of Texas MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00883688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 25, 2020 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00883688 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →